Cargando…
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor
In our previous study, we found that inhibition of protein tyrosine phosphatase non-receptor type 3 (PTPN3), which is expressed in lymphocytes, enhances lymphocyte activation, suggesting PTPN3 may act as an immune checkpoint molecule. However, PTPN3 is also expressed in various cancers, and the biol...
Autores principales: | Koga, Satoko, Onishi, Hideya, Masuda, Shogo, Fujimura, Akiko, Ichimiya, Shu, Nakayama, Kazunori, Imaizumi, Akira, Nishiyama, Kenichi, Kojima, Masayuki, Miyoshi, Kei, Nakamura, Katsuya, Umebayashi, Masayo, Morisaki, Takashi, Nakamura, Masafumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208899/ https://www.ncbi.nlm.nih.gov/pubmed/34134073 http://dx.doi.org/10.1016/j.tranon.2021.101152 |
Ejemplares similares
-
Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152]
por: Koga, Satoko, et al.
Publicado: (2022) -
C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions
por: Nagao, Shinjiro, et al.
Publicado: (2023) -
GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer
por: Ichimiya, Shu, et al.
Publicado: (2021) -
FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients
por: Saeki, Kiyoshi, et al.
Publicado: (2020) -
Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
por: Morisaki, Shinji, et al.
Publicado: (2023)